Wiesner L, Araya S, Lovsin Barle E. Identifying non-hazardous substances in pharmaceutical manufacturing and setting default Health-Based Exposure Limits (HBELs).
J Appl Toxicol 2022;
42:1443-1457. [PMID:
35315528 DOI:
10.1002/jat.4323]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 03/02/2022] [Accepted: 03/16/2022] [Indexed: 11/07/2022]
Abstract
Contract Development and Manufacturing Organizations (CDMOs) that manufacture large, diverse portfolio of chemical and pharmaceutical substances require pragmatic risk-based decisions with respect to the safe carry-over between different chemical entities, as well as for worker protection. Additionally, CDMOs may not have access to primary study data or data is generally lacking for a specific substance. While pharmaceuticals require the establishment of health-based exposure limits (HBELs) (e.g., occupational exposure limits, permitted daily exposure limits), the limits for non-hazardous substances could be set in a protective and pragmatic way by using default values, when internally required. Since there is no aligned definition provided by authorities, nor agreed default values for non-hazardous substances, we provide a decision tree in order to help qualified experts (such as qualified toxicologists) to identify the group of non-hazardous substances and to assign default HBEL values for specific routes of exposure. The non-hazardous substances discussed within this publication are part of the following subgroups: (I) inactive pharmaceutical ingredients, (II) pharmaceutical excipients or cosmetic ingredients, (III) substances Generally Recognized as Safe (GRAS), and (IV) food ingredients, additives and contact materials. The proposed default limit values are 1 mg/m3 for the OEL, and 50 mg/day for the PDE oral and IV (intravenous) route.
Collapse